Westwood Holdings Group Inc. Decreases Position in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Westwood Holdings Group Inc. lowered its position in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 6.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 804,480 shares of the company's stock after selling 55,508 shares during the quarter. Westwood Holdings Group Inc. owned approximately 1.63% of Prestige Consumer Healthcare worth $62,822,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also bought and sold shares of PBH. Barclays PLC boosted its stake in Prestige Consumer Healthcare by 346.3% in the third quarter. Barclays PLC now owns 92,444 shares of the company's stock worth $6,665,000 after buying an additional 71,730 shares in the last quarter. Franklin Resources Inc. lifted its position in Prestige Consumer Healthcare by 4.3% in the third quarter. Franklin Resources Inc. now owns 21,585 shares of the company's stock valued at $1,513,000 after purchasing an additional 894 shares during the last quarter. Assenagon Asset Management S.A. lifted its position in Prestige Consumer Healthcare by 171.6% in the fourth quarter. Assenagon Asset Management S.A. now owns 46,931 shares of the company's stock valued at $3,665,000 after purchasing an additional 29,649 shares during the last quarter. Diversify Wealth Management LLC lifted its position in Prestige Consumer Healthcare by 35.3% in the fourth quarter. Diversify Wealth Management LLC now owns 10,399 shares of the company's stock valued at $770,000 after purchasing an additional 2,713 shares during the last quarter. Finally, SG Americas Securities LLC lifted its position in Prestige Consumer Healthcare by 18.8% in the fourth quarter. SG Americas Securities LLC now owns 5,996 shares of the company's stock valued at $468,000 after purchasing an additional 947 shares during the last quarter. Hedge funds and other institutional investors own 99.95% of the company's stock.

Prestige Consumer Healthcare Stock Up 1.1%

Prestige Consumer Healthcare stock traded up $0.97 on Friday, hitting $85.98. 341,432 shares of the stock traded hands, compared to its average volume of 297,623. The company has a current ratio of 3.68, a quick ratio of 2.20 and a debt-to-equity ratio of 0.56. The firm has a market cap of $4.25 billion, a P/E ratio of 20.14, a price-to-earnings-growth ratio of 2.69 and a beta of 0.44. The business's fifty day simple moving average is $83.52 and its 200 day simple moving average is $82.25. Prestige Consumer Healthcare Inc. has a 1 year low of $62.35 and a 1 year high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported $1.32 EPS for the quarter, beating the consensus estimate of $1.30 by $0.02. The business had revenue of $296.52 million during the quarter, compared to analyst estimates of $289.36 million. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. The company's revenue for the quarter was up 7.0% on a year-over-year basis. During the same quarter last year, the firm posted $1.02 earnings per share. As a group, sell-side analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have weighed in on PBH. DA Davidson boosted their price objective on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a "buy" rating in a research report on Friday, February 7th. Oppenheimer raised their price target on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an "outperform" rating in a research note on Thursday, February 13th. Royal Bank of Canada raised Prestige Consumer Healthcare to a "hold" rating in a research note on Thursday, May 8th. Canaccord Genuity Group raised their price target on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a "buy" rating in a research note on Friday, February 7th. Finally, Wall Street Zen raised Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research note on Saturday, May 17th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $93.33.

Insider Activity at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, SVP Mary Beth Fritz sold 1,678 shares of Prestige Consumer Healthcare stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $90.00, for a total value of $151,020.00. Following the completion of the transaction, the senior vice president now directly owns 17,157 shares of the company's stock, valued at approximately $1,544,130. The trade was a 8.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 1.60% of the stock is currently owned by insiders.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.